2
Clinical Trials associated with Tezepelumab biosimilar (Qilu) / Not yet recruitingPhase 3 A Multi-center, Randomised, Double Blind, Active Controlled Phase III Trial to Compare the Efficacy and Safety of QL2302 With Tezspire® in Adults With Uncontrolled Severe Asthma
The goal of this clinical trial is to compare the efficacy and safety of QL2302 and Tezspire® in patients with uncontrolled severe asthma. The main questions it aims to answer are:
* if the efficacy of QL2302 and Tezspire® are similar
* if the safety of QL2302 and Tezspire® are similar
Participants will be randomised to QL2302 or Tezspire® group and asked to receive one injection of QL2302 or Tezspire® subcutaneously every four weeks till Week 48, which means participants will receive a total of 13 injections. And be observed for another 12 weeks after the end of treatment.
Start Date25 Dec 2025 |
Sponsor / Collaborator- |
/ Not yet recruitingPhase 1 A Randomized, Double-blinded, Parallel, Positive-controlled Study to Compare the Pharmacokinetic, Safety and Immunogenicity of Single-dose QL2302 vs. Tezspire ® in Healthy Subjects
This is a randomized, double-blinded, controlled Phase 1 study to compare the pharmacokinetic, safety and immunogenicity of QL2302 versus Tezspire®(Tezepelumab) in healthy subjects after a single dose.
100 Clinical Results associated with Tezepelumab biosimilar (Qilu)
100 Translational Medicine associated with Tezepelumab biosimilar (Qilu)
100 Patents (Medical) associated with Tezepelumab biosimilar (Qilu)
100 Deals associated with Tezepelumab biosimilar (Qilu)